Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year target prices for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they expect the company's share price to reach $37.75 in the next year. This suggests a possible upside of 73.2% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO stock has decreased by 22.4% and is now trading at $21.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AGIO earnings forecast.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating the consensus estimate of ($1.57) by $0.09. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 20.68% and a negative net margin of 1,627.82%. During the same period in the previous year, the business posted ($1.43) earnings per share.

ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Goldman Sachs Future Health Care Equity ETF (GDOC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and WisdomTree U.S. SmallCap Fund (EES).

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (5.01%), Dimensional Fund Advisors LP (3.01%), First Trust Advisors LP (2.97%), Price T Rowe Associates Inc. MD (2.69%), ArrowMark Colorado Holdings LLC (2.62%) and Macquarie Group Ltd. (2.57%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGIO stock can currently be purchased for approximately $21.79.

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.20 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($4.24) on an earnings per share basis.

The company employs 390 workers across the globe.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.